“If this pans out, this could be a real game changer,” Dr. Jose Baselga, physician in chief at Memorial Sloan Kettering and a member of GRAIL’s advisory board, said during the conference call,
according to The New York Times.
Some experts cautioned that obstacles remain even if the presymptomatic cancer screening test is developed. Will the test find all cancers or potentially give wrong results? Some early-stage cancers may never cause harm but patients may nonetheless be exposed to expensive and aggressive treatments. Other companies are also pursuing similar tests known as liquid biopsies to be part of a market that may grow from $20 billion to as much as $200 billion if blood screening can eventually detect stage 1 cancers.
Ad Statistics
Times Displayed: 61669
Times Visited: 2014 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
But MIT Technology Review notes that Flatley believes GRAIL’s advantage will be the sequencing technology provided by Illumina that will help it keep its costs lower than competitors.
“In this case, we didn’t think the market could do it fast enough, unless we destroyed our (business) by giving away sequencing,” Flatley said. “We don’t think anyone else can do it at scale.”
Back to HCB News
